Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 371

1.

Isolation and characterization of iron chelators from turmeric (Curcuma longa): selective metal binding by curcuminoids.

Messner DJ, Surrago C, Fiordalisi C, Chung WY, Kowdley KV.

Biometals. 2017 Aug 11. doi: 10.1007/s10534-017-0038-6. [Epub ahead of print]

PMID:
28801864
2.

Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.

Curry MP, Tapper EB, Bacon B, Dieterich D, Flamm SL, Guest L, Kowdley KV, Lee Y, Milligan S, Tsai N, Younossi Z, Afdhal NH.

Aliment Pharmacol Ther. 2017 Sep;46(5):540-548. doi: 10.1111/apt.14204. Epub 2017 Jul 10.

PMID:
28691377
3.

Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment.

Lok AS, Ganova-Raeva L, Cloonan Y, Punkova L, Lin HS, Lee WM, Ghany MG; Hepatitis B Research Network (HBRN).

J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12732. [Epub ahead of print]

PMID:
28581155
4.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators.

N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.

PMID:
28564569
5.

Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children.

Newton KP, Feldman HS, Chambers CD, Wilson L, Behling C, Clark JM, Molleston JP, Chalasani N, Sanyal AJ, Fishbein MH, Lavine JE, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).

J Pediatr. 2017 Aug;187:141-146.e1. doi: 10.1016/j.jpeds.2017.03.007. Epub 2017 Mar 30.

PMID:
28366357
6.

Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease.

Hsu CC, Ness E, Kowdley KV.

Adv Nutr. 2017 Mar 15;8(2):253-265. doi: 10.3945/an.116.013730. Print 2017 Mar. Review.

PMID:
28298270
7.

Curcumin and Turmeric Modulate the Tumor-Promoting Effects of Iron In Vitro.

Messner DJ, Robinson T, Kowdley KV.

Nutr Cancer. 2017 Apr;69(3):481-489. doi: 10.1080/01635581.2017.1274407. Epub 2017 Jan 27.

PMID:
28129008
8.

 Differences in hepatic expression of iron, inflammation and stress-related genes in patients with nonalcoholic steatohepatitis.

Handa P, Vemulakonda AL, Maliken BD, Morgan-Stevenson V, Nelson JE, Dhillon BK, Hennessey KA, Gupta R, Yeh MM, Kowdley KV.

Ann Hepatol. 2017 Jan-Feb 2017;16(1):77-85. doi: 10.5604/16652681.1226818.

9.

Iron Overload in Patients With Chronic Liver Disease.

Kowdley KV.

Gastroenterol Hepatol (N Y). 2016 Nov;12(11):695-698. No abstract available.

10.

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.

Kowdley KV, Sundaram V, Jeon CY, Qureshi K, Latt NL, Sahota A, Lott S, Curry MP, Tsai N, Chaiyakunapruk N, Lee Y, Petersen J, Buggisch P.

Hepatology. 2017 Apr;65(4):1094-1103. doi: 10.1002/hep.29005. Epub 2017 Feb 25. Review.

PMID:
28027579
11.

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease.

Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson EJ, Schlicht EM, Liu JZ, Shah T, Gutierrez-Achury J, Boberg KM, Bergquist A, Vermeire S, Eksteen B, Durie PR, Farkkila M, Müller T, Schramm C, Sterneck M, Weismüller TJ, Gotthardt DN, Ellinghaus D, Braun F, Teufel A, Laudes M, Lieb W, Jacobs G, Beuers U, Weersma RK, Wijmenga C, Marschall HU, Milkiewicz P, Pares A, Kontula K, Chazouillères O, Invernizzi P, Goode E, Spiess K, Moore C, Sambrook J, Ouwehand WH, Roberts DJ, Danesh J, Floreani A, Gulamhusein AF, Eaton JE, Schreiber S, Coltescu C, Bowlus CL, Luketic VA, Odin JA, Chopra KB, Kowdley KV, Chalasani N, Manns MP, Srivastava B, Mells G, Sandford RN, Alexander G, Gaffney DJ, Chapman RW, Hirschfield GM, de Andrade M; UK-PSC Consortium; International IBD Genetics Consortium; International PSC Study Group, Rushbrook SM, Franke A, Karlsen TH, Lazaridis KN, Anderson CA.

Nat Genet. 2017 Feb;49(2):269-273. doi: 10.1038/ng.3745. Epub 2016 Dec 19.

12.

Association between metabolic syndrome and liver histology among NAFLD patients without diabetes.

Kanwar P, Nelson JE, Yates K, Kleiner DE, Unalp-Arida A, Kowdley KV.

BMJ Open Gastroenterol. 2016 Nov 9;3(1):e000114. eCollection 2016.

13.

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.

Wyles D, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Martin R, Afdhal NH, Kowdley KV, Lawitz E, Brainard DM, Miller MD, Mo H, Gane EJ.

J Hepatol. 2017 Apr;66(4):703-710. doi: 10.1016/j.jhep.2016.11.022. Epub 2016 Dec 5.

PMID:
27923693
14.

Determination of hepatitis B phenotype using biochemical and serological markers.

Di Bisceglie AM, Lombardero M, Teckman J, Roberts L, Janssen HL, Belle SH, Hoofnagle JH; Hepatitis B Research Network (HBRN).

J Viral Hepat. 2017 Apr;24(4):320-329. doi: 10.1111/jvh.12643. Epub 2016 Dec 5.

PMID:
27917600
15.

Update on hepatitis C treatment: systematic review of clinical trials.

Jhaveri M, Procaccini N, Kowdley KV.

Minerva Gastroenterol Dietol. 2017 Mar;63(1):62-73. doi: 10.23736/S1121-421X.16.02345-X. Epub 2016 Oct 21.

PMID:
27768010
16.

Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.

Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM, Afdhal NH.

J Viral Hepat. 2017 Jan;24(1):22-27. doi: 10.1111/jvh.12611. Epub 2016 Oct 11.

PMID:
27730717
17.

Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.

Nelson JE, Handa P, Aouizerat B, Wilson L, Vemulakonda LA, Yeh MM, Kowdley KV; NASH Clinical Research Network.

Aliment Pharmacol Ther. 2016 Dec;44(11-12):1253-1264. doi: 10.1111/apt.13824. Epub 2016 Oct 11.

PMID:
27730688
18.

Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?

Handa P, Vemulakonda A, Kowdley KV, Uribe M, Méndez-Sánchez N.

World J Gastroenterol. 2016 Aug 21;22(31):6965-71. doi: 10.3748/wjg.v22.i31.6965.

19.

Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.

Tapper EB, Bacon BR, Curry MP, Dieterich DT, Flamm SL, Guest LE, Kowdley KV, Lee Y, Tsai NC, Younossi ZM, Afdhal NH.

Hepatology. 2016 Dec;64(6):1893-1899. doi: 10.1002/hep.28782. Epub 2016 Oct 5.

PMID:
27533287
20.

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group.

N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840.

Supplemental Content

Loading ...
Support Center